{"paper_id":"df942711-3d34-4267-af7a-79e32deda65d","body_text":"Abstract\nIntroduction and hypothesis\nWe evaluated the association between previous hysterectomy for uterine fibroids and the risk of developing overactive bladder (OAB).\nMethods\nWe used national health insurance data. The hysterectomy group (aged 40 to 59) comprised patients who underwent hysterectomy for uterine leiomyoma or adenomyosis between 1 January 2011 and 31 December 2014, and the control group (aged 40 to 59) comprised patients who visited a medical facility for a checkup during the same time period. Propensity score matching (PSM, 1:1) was performed to balance confounders. OAB events were defined by drug prescriptions (beta 3 agonist or anticholinergics) for more than 1 month based on previous studies.\nResults\nAfter matching, 58,195 cases (hysterectomy group) and 58,195 controls (nonhysterectomy group) were enrolled. The mean follow-up period was 7.9 years in the nonhysterectomy group and 8.0 years in the hysterectomy group. There was no significant difference in the rate of OAB development between the groups (0.3% vs 0.3%; p=0.061). Additionally, compared with the nonhysterectomy group (hazard ratio: 1 (reference)), hysterectomy without adnexal surgery (hazard ratio: 1.169 [0.915–1.493]) and hysterectomy with adnexal surgery (hazard ratio: 1.342 [0.83–2.171]) did not significantly increase the risk of OAB after adjusting for confounders; this relationship remained nonsignificant after stratifying patients according to age group.\nConclusions\nPrevious hysterectomy with or without adnexal surgery for the treatment of uterine fibroids did not increase the risk of developing OAB, defined as drug therapy lasting more than 1 month.\nSimilar content being viewed by others\nReferences\nPeyronnet B, Mironska E, Chapple C, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. 2019;75(6):988–1000.\nIrwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–15.\nLin X-D, Lin N, Ke Z-B, Xu N, Jiang P, Li H. Effects of overactive bladder syndrome on female sexual function. Medicine. 2021;100(20);e25761.\nRaju R, Linder BJ. Evaluation and treatment of overactive bladder in women. Mayo Clin Proc. 2020;95(2):370–7.\nHerbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ. 2003;326(7394):841.\nChapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–62.\nSolifenacin and darifenacin for overactive bladder. Obstet Gynecol. 2005;106(2):401–2. https://doi.org/10.1097/01.AOG.0000173816.33966.ed.\nThomas TN, Walters MD. AUGS consensus statement: association of anticholinergic medication use and cognition in women with overactive bladder. Female Pelvic Med Reconstr Surg. 2017;23(3):177–8.\nWang J, Zhou Z, Cui Y, et al. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn. 2019;38(1):22–30.\nAcar Ö, Erton ML, Tarcan T. Insights into the management of overactive bladder: what difference can mirabegron make? J Urol Surg. 2019;6(2):85.\nBaird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100–7.\nLee M, Chung Y-J, Kim H-K, et al. Estimated prevalence and incidence of uterine leiomyoma, and its treatment trend in south Korean women for 12 years: a national population-based study. J Womens Health. 2021;30(7):1038–46.\nVilos GA, Allaire C, Laberge P-Y, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can. 2015;37(2):157–78.\nMadueke-Laveaux OS, Elsharoud A, Al-Hendy A. What we know about the long-term risks of hysterectomy for benign indication—a systematic review. J Clin Med. 2021;10(22):5335.\nLi P-C, Huang H-K, Ding D-C. Hysterectomy associated with de novo lower urinary tract symptoms in a Taiwanese population: a nationwide, population-based study. Int Urogynecol J. 2019;30(10):1711–7.\nSelcuk S, Cam C, Asoglu MR, et al. Effect of simple and radical hysterectomy on quality of life–analysis of all aspects of pelvic floor dysfunction. Eur J Obstet Gynecol Reprod Biol. 2016;198:84–8.\nBerujon E, Thubert T, Fauvet R, Villot A, Pizzoferrato A-C. Impact of uterine fibroid surgery on lower urinary tract symptoms. J Gynecol Obstet Human Reprod. 2022;51(5):102355.\nTikkinen KA, Auvinen A, Tiitinen A, Valpas A, Johnson TM II, Tammela TL. Reproductive factors associated with nocturia and urinary urgency in women: a population-based study in Finland. Am J Obstet Gynecol. 2008;199(2):153.e1–12.\nAltman D, López A, Falconer C, Zetterström J. The impact of hysterectomy on lower urinary tract symptoms. Int Urogynecol J. 2003;14(6):418–23.\nKim L, Kim J-A, Kim S. A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health. 2014;36:e2014008.\nUlin M, Ali M, Chaudhry ZT, Al-Hendy A, Yang Q. Uterine fibroids in menopause and perimenopause. Menopause. 2020;27(2):238.\nHwang S, Kang SW, Choi KJ, et al. Early menopause is associated with increased risk of retinal vascular occlusions: a nationwide cohort study. Sci Rep. 2022;12(1):1–10.\nLi J-R, Wang S-S, Lin C-H, De Groat WC, Cheng C-L. Positive association of male overactive bladder symptoms and androgen deprivation: a nationwide population-based cohort study. Anticancer Res. 2019;39(1):305–11.\nCheng C-L, Li J-R, Lin C-H, de Groat WC. Positive association of female overactive bladder symptoms and estrogen deprivation: a nationwide population-based cohort study in Taiwan. Medicine. 2016;95(28):e4107.\nHaab F, Castro-Diaz D. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract. 2005;59(8):931–7.\nQuan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–82.\nIosif CS, Batra S, Ek A, Åstedt B. Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol. 1981;141(7):817–20.\nVersi E, Harvey M-A, Cardozo L, Brincat M, Studd J. Urogenital prolapse and atrophy at menopause: a prevalence study. Int Urogynecol J. 2001;12(2):107–10.\nDeLancey JO. Anatomic aspects of vaginal eversion after hysterectomy. Am J Obstet Gynecol. 1992;166(6):1717–28.\nMaas CP, Kenter GG, Trimbos JB, Deruiter MC. Anatomical basis for nerve-sparing radical hysterectomy: immunohistochemical study of the pelvic autonomic nerves. Acta Obstet Gynecol Scand. 2005;84(9):868–74.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEthics declarations\nConflicts of interest\nNone.\nAdditional information\nPublisher’s note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nSupplementary Information\nESM 1 (download DOCX )\n(DOCX 12 kb)\nRights and permissions\nSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.\nAbout this article\nCite this article\nYuk, JS., Lee, J.H. Risk of overactive bladder after hysterectomy for uterine fibroids. Int Urogynecol J 34, 1823–1829 (2023). https://doi.org/10.1007/s00192-023-05474-9\nReceived:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s00192-023-05474-9","source_license":"CC0","license_restricted":false}